Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9713370 | 0.90 | ADRB2 (0.59) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL4812224 | 0.87 | ADRB2 (0.59) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL7988695 | 0.85 | KDM4E (0.60) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL9713100 | 0.84 | TTR (0.58) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL1322956 | 0.84 | KDM4E (0.64) | MTNR1AMTNR1B | |
| SCHEMBL10526510 | 0.83 | EBP (0.68) | — | |
| SCHEMBL3511041 | 0.83 | ADRB2 (0.53) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL3510320 | 0.83 | ADRB2 (0.53) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL12124783 | 0.82 | HDAC1 (0.53) | — | |
| SCHEMBL458350 | 0.82 | KCNH2 (0.50) | ADRB2DRD2DRD1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326801-B2 | 2-amino-propanol derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| EP-1377593-B1 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040147490-A1 | 2-Amino-propanol derivatives | ALBERT RAINER (CH) | 2004-07-29 | — | — | US | disclosed |
| EP-1377593-A2 | 2-AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002076995-A2 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147490-A1 | 2-Amino-propanol derivatives | CD4, HLA-DRB1, CCR1 | ADRB2 4/4885DRD2 150/4885DRD1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.